India · Delayed Price · Currency is INR Eris Lifesciences Earnings Call Transcripts
Fiscal Year 2026
-
Q3 and nine-month results showed double-digit growth in revenue and profits, with strong performance in branded formulations and international business. Margin expansion, new product launches, and a robust CDMO order book support a positive outlook, while CapEx is being front-loaded for strategic growth.
-
Q2 saw 10% domestic revenue growth and 11% EBITDA growth, with Biocon margins rising to 32%. International business expanded, and the European CDMO order book reached INR 700-800 crore. CapEx is front-loaded, with net debt-to-EBITDA expected below 1.5x by Dec 2026.
-
DBF segment delivered 11% revenue growth and 37% EBITDA margin, while consolidated profit after tax rose 41% year-on-year. Insulin and GLP-1 capacity expansions are on track, and the international business is pivoting to higher-margin EU markets with confirmed CDMO contracts.
Fiscal Year 2025
-
Q4 revenue grew 28% year-on-year to INR 705 crores, with EBITDA up 70% and strong margin expansion. FY 2025 saw robust growth in DBF and Swiss Parenterals, improved ROCE, and significant debt reduction, with FY 2026 guidance projecting continued double-digit growth and margin improvement.
-
Q3 and YTD saw strong revenue and EBITDA growth, with margins expanding and debt reduction ahead of schedule. Strategic investments in biologics and new product launches are set to drive future growth, with a major GLP-1 market entry planned for 2026.
-
Q2 revenue grew 47% year-over-year to INR 741 crores, with EBITDA up 46% and margins stable. Integration of acquisitions and manufacturing improvements drove margin expansion and cost synergies. Guidance for FY 2025 is reaffirmed, with new product launches and strategic investments set to support future growth.
-
Q1 FY25 saw 54% revenue growth and 47% EBITDA growth, driven by strong integration of Biocon acquisitions and margin expansion. FY25 guidance targets INR 3,000+ crore revenue and 35% EBITDA margin, with significant investments in biotech and debt reduction underway.